Asthlon Special Precautions

Budesonide nebulizing suspension is not intended for rapid relief acute episodes of asthma where an inhaled short-acting bronchodilator is required. If patients find short-acting bronchodilators treatment ineffective, or they need more inhalations than usual, medical attention must be sought. In this situation, consideration should be given to the need for increased anti-inflammatory therapy, e.g. higher doses of inhaled budesonide or a course of oral glucocorticosteroid.
Reduced liver function may affect the elimination of corticosteroids. This may be clinically relevant in patients with severely compromised liver function.
In vivo studies have shown that oral administration of ketoconazole and itraconazole (known inhibitors of CYP3A4 activity in the liver and in the intestinal mucosa) may cause an increase of the systemic exposure to budesonide.
The long term local and systemic effects of Budesonide Nebulizing Suspension in man are not completely known. The dose should be titrated to the lowest effective maintenance dose once control of asthma is achieved. Physicians should closely monitor the growth of children taking corticosteroids by any route and weigh the benefit of corticosteroid therapy and asthma control against the possibility of growth suppression.
Budesonide does not affect the ability to drive and use machines.